

세미나 초록

성명	정철웅
소속	레고켄바이오
발표 주제	항체-약물 접합체 성과와 숙제
발표 내용	<p>Despite the recent remarkable progress made in the field of anticancer drug development, drug resistance and toxicity are the biggest reasons for hindering the treatment of patients. This phenomenon is also happening in ADC, which has recently received a lot of attention due to surprising clinical results. Antibody–drug conjugates (ADC) are designed to deliver potent payloads to cancer cells via tumor-specific antigens and antibody interaction. Although it was designed to potentiate safety and efficacy, still it was not reached at the level of expected. Recent studies reveal potential mechanisms of those hurdles. Because ADCs are a combination of antibody and small molecule cytotoxin, various mechanisms are involved in. In this presentation, I will list reasons why we couldn't get to the goal yet and discuss strategies on how to overcome this resistance</p>